Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
Version 3 2024-06-19, 12:08Version 3 2024-06-19, 12:08
Version 2 2024-06-13, 17:15Version 2 2024-06-13, 17:15
Version 1 2022-10-25, 22:31Version 1 2022-10-25, 22:31
journal contribution
posted on 2024-06-19, 12:08authored byT Barbour, M Scully, G Ariceta, S Cataland, K Garlo, N Heyne, Y Luque, J Menne, Y Miyakawa, SS Yoon, D Kavanagh, S Babu, N Broeders, N Lietar, F Brown, P Campbell, JM Campistol, P Chowdhury, T Kasimatis, L Cirami, L Caroti, G Antognoli, Y Delmas, V Dobronravov, A Gaeckler, C Garrouste, G Greenwood, S Griffin, CC Huang, IR Chen, S Huang, JS Kim, G La Manna, M Le Quintrec, G Jeantet, I Fumie, E Rondeau, H Haller, J Morelle, E Goffin, A Muhlfeld, S Nagaraj, G Arepally, D Oh, M Okumi, MP Terente, F Provot, U Schönermarck, M Fischereder, NR Terrada, B Seitz-Polski, G Favre, S Boyer-Suavet, M Vinogradova, T Kirsanova, EKS Wong
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults